论文部分内容阅读
【目的】探讨叶酸辅助治疗精神分裂症阴性症状患者的临床疗效及安全性。【方法】采用随机双盲对照法，将106例以阴性症状为主且单一使用哌罗匹隆治疗的精神分裂症患者分为观察组（ n ＝53，给予叶酸）和对照组（ n ＝53，给予安慰剂），治疗周期为12周。分别于治疗前，治疗第4、8、12周末使用阴性症状评定量表（SANS）评定疗效，使用副反应量表（TESS）评定药物不良反应。【结果】两组SANS总分在治疗第4、8、12周末均较治疗前有明显下降，具有统计学意义（ P ＜0．05）；与对照组相比，观察组第4、8、12周末SANS总分均低于对照组，且差异具有统计学意义（ P ＜0．05，P ＜0．01）。治疗第12周末观察组SANS减分率高于对照组，差异具有统计学意义（P ＜0．05）。两组不良反应发生率无统计学差异（P ＞0．05）。【结论】叶酸有助于改善精神分裂症患者的阴性症状，且安全性好。“,”[Objective] To evaluate the clinical efficacy and safety of folic acid in the treatment of negative symptoms in schizophrenics .[Methods] For this double‐blind controlled trial ,a total of 106 schizophrenics with predominantly negative symptoms on a monotherapy of perospirone hydrochloride were assigned into trial (folic acid ,n =53) and control (placebo ,n =53) groups .During an observation period of 12 weeks ,all par‐ticipants completed the scales of scale for the assessment of negative symptoms (SANS) and treatment emer‐gent symptom scale (TESS) to assess the status of negative symptoms and adverse drug reactions at baseline and at the end of weeks 4 ,8 and 12 of treatment .[Results] Compared with baseline data ,the total SANS scores of both two groups significantly decreased at weeks 4 ,8 and 12 .And the differences had statistical sig‐nificance ( P <0 .05) .The mean total SANS scores of study group were lower than those of control group at weeks 4 ,8 and 12 .And inter‐group differences existed ( P <0 .05 ,P <0 .01) .Furthermore ,study group had a higher declining rate than control group at week 12 .And the changes showed significant inter‐group differences ( P0 .05) .[Conclusion]Folic acid is both effective and safe for improving negative symptoms in schizophrenics .